Plainsboro, NJ, United States of America

Jianguo Yin

This inventor holds 15 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 7 EPO patents. Top assignees: Merck Sharp + Dohme Corp., Schering Corporation. Active years: 2006-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jianguo Yin. Retrieved from https://idiyas.com/inventor/jianguo-yin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15 (Patent Applications = 1)

% Patents Active = 66.7

CIPO Patents = 1

EPO Patents = 7 (Patent Applications = 6)

Average Co-Inventor Count = 7.3

ph-index = 5

Forward Citations = 81(Granted Patents)

Location History:

Edison, NJ (US) (2006 - 2011)
Plainsboro, NJ (US) (2010 - 2019)

Company Filing History:

8 out of 2,405

Merck Sharp + Dohme Corp.

Years Active: 2006-2019

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10464937 - Process for preparing beta-lactamase inhibitor hydroxylurea intermediates (2019-11-05),

2. 10457690 - Process for preparing substituted tetracyclic heterocycle compounds (2019-10-29),

3. 10106541 - Intermediates for preparing CGRP receptor antagonists (2018-10-23),

4. 9850246 - Process for making CGRP receptor antagonists (2017-12-26),

5. 9487523 - Process for making CGRP receptor antagonists (2016-11-08),

6. 9174989 - Process for making CGRP receptor antagonists (2015-11-03),

7. 8519168 - Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds (2013-08-27),

8. 8329905 - Synthesis of diethyl{[5-(3-fluorophenyl)-pyridine-2yl]methyl}phosphonate (2012-12-11),

9. 8207221 - Crystalline polymorphs of a CXC-chemokine receptor ligand (2012-06-26),

10. 7985860 - Process and intermediates for the synthesis of 2-(quinolin-5-yl)-4,5 disubstituted-azole derivatives (2011-07-26),

11. 7956189 - Maleate, tosylate, fumarate and oxalate salts of 5-(1-(S)-amino-2-hydroxyethyl)-N-[(2,4-difluorophenyl)-methy]-2-[8-methoxy-2-(triflouromethy)-5-quinoline]-4-oxazolecarboxamide and preparation process therefore (2011-06-07),

12. 7910775 - Synthesis of 2-Hydroxy-N,N-dimethyl-3-[[2-[[1(R)-(5-methyl-2-furanyl)propyl]amino]-3,4-dioxo-1-cyclobuten-1-yl]amino]benzamide (2011-03-22),

13. 7687631 - Synthesis of diethyl{[5-(3-fluorophenyl)-pyridine-2yl]methyl}phosphonate (2010-03-30),

14. 7462740 - Synthesis of 2-hydroxy-n,n-dimethyl-3-[[2-[[1(r)-(5-methyl-2-furanyl)propyl]amino]-3,4-dioxo-1-cyclobuten-1-yl]amino]benzamide (2008-12-09),

15. 7071342 - Synthesis of 2-hydroxy-N,N-dimethyl-3-[ [2-[1 (R)-(5-methyl-2-furanyl)propyl]amino]-3,4-dioxo-1-cyclobuten-1-yl]aminobenzamide (2006-07-04),

Title: **The Innovative Contributions of Jianguo Yin in Patent Development**

Introduction

Jianguo Yin, an accomplished inventor based in Plainsboro, NJ, has made significant strides in the field of chemical research and development. With a total of 15 patents to his name, Jianguo has demonstrated his expertise and creativity in crafting innovative solutions, particularly in the area of pharmaceuticals.

Latest Patents

Among his most notable recent patents is a method for preparing beta-lactamase inhibitor hydroxylurea intermediates. This invention relates to the processes for the preparation of N-protected (2S,5R)-6-hydroxy-7-oxo-N-piperidin-4-yl-1,6-diazabicyclo[3.2.1]octane-2-carboxamide intermediates. These compounds are crucial for developing beta-lactamase inhibitors, including (2S,5R)-7-oxo-N-piperidin-4-yl-6-(sulfoxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide.

Additionally, Jianguo has developed processes for preparing substituted tetracyclic heterocycle compounds, which serve as potential HCV NS5A inhibitors. This patent includes compounds that can act as synthetic intermediates and catalysts, further showcasing Jianguo's innovative approaches in pharmaceutical development.

Career Highlights

Jianguo Yin has worked diligently at prestigious companies, including Merck Sharp & Dohme Corporation and Schering Corporation. His experiences in these organizations have significantly contributed to his expertise and inventive capabilities in addressing complex challenges in drug development.

Collaborations

Throughout his career, Jianguo has collaborated with notable colleagues such as Xiaoyong Fu and Shuyi Zhang. These collaborations reflect the importance of teamwork and shared knowledge in driving innovation and producing impactful patents in the pharmaceutical realm.

Conclusion

In summary, Jianguo Yin exemplifies the qualities of a successful inventor through his inventive contributions to pharmaceutical science. His recent patents not only emphasize his ingenuity but also highlight the essential role of collaboration within the research community. As a key figure in the industry, Jianguo continues to pave the way for advancements in drug development and innovation.

Profile summary based on public USPTO records.